On February 27, 2023, the U.S. Food and Drug Administration (FDA) released a letter informing health care providers about the potential risk of early structural valve deterioration (SVD) with Abbott Trifecta valves, including the Trifecta Valve and the Trifecta Valve with Glide Technology (Trifecta GT).

The FDA is encouraging providers to report adverse events related to Trifecta valves to the FDA and recommends that providers monitor patients who have undergone implantation with Trifecta valves for signs and symptoms of potential SVD.

See the FDA letter and the Abbott letter for more information.